Sava Infond d.o.o. Acquires Shares of 21,000 Royalty Pharma plc (NASDAQ:RPRX)

Sava Infond d.o.o. acquired a new stake in shares of Royalty Pharma plc (NASDAQ:RPRX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 21,000 shares of the biopharmaceutical company’s stock, valued at approximately $536,000.

Several other large investors have also recently made changes to their positions in the company. Brooklyn Investment Group grew its holdings in Royalty Pharma by 1,006.9% during the 4th quarter. Brooklyn Investment Group now owns 963 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 876 shares in the last quarter. Allworth Financial LP increased its position in Royalty Pharma by 417.6% in the fourth quarter. Allworth Financial LP now owns 1,087 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 877 shares during the last quarter. Riverview Trust Co raised its stake in Royalty Pharma by 3,953.3% during the fourth quarter. Riverview Trust Co now owns 1,216 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,186 shares in the last quarter. Fifth Third Bancorp lifted its position in Royalty Pharma by 187.1% during the fourth quarter. Fifth Third Bancorp now owns 1,530 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 997 shares during the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Royalty Pharma by 31.3% in the 4th quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 376 shares in the last quarter. 54.35% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, TD Cowen upgraded shares of Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $41.60.

Royalty Pharma Trading Up 0.3 %

Shares of RPRX opened at $31.65 on Friday. Royalty Pharma plc has a twelve month low of $24.05 and a twelve month high of $34.20. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The company’s fifty day simple moving average is $32.43 and its 200-day simple moving average is $28.82. The company has a market cap of $18.24 billion, a P/E ratio of 21.83, a P/E/G ratio of 2.31 and a beta of 0.47.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, analysts expect that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, March 10th. Shareholders of record on Friday, February 21st were given a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 2.78%. The ex-dividend date of this dividend was Friday, February 21st. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. Royalty Pharma’s dividend payout ratio is 60.69%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.